Association of Psoriasis Severity with Serum Prolactin, Thyroid Hormones, and Cortisol before and after Treatment
Table 1
Summary of serum levels of PRL, cortisol, and thyroid hormones based on study groups.
Cases ()
Controls ()
Before treatment ()
After treatment ()
Prolactina, (ng/mL)
14.08 ± 7.36; 11.80 (4.8–41.2)
11.57 ± 5.00; 11.00 (5–23.2)
13.14 ± 10.09; 10.65 (3.9–41.9)
Female
14.22 ± 9.06; 11.45 (4.8–41.2)
11.60 ± 3.29; 11.90 (6.4–17.3)
16.74 ± 13.37; 10.85 (4.0–41.9)
Male
13.96 ± 5.78; 12.90 (5.3–22.6)
11.54 ± 6.16; 8.40 (5–23.2)
9.99 ± 4.36; 10.65 (3.9–21.2)
Cortisolb, (ng/mL)
146.07 ± 63.66; 131 (67–387)
169.04 ± 61.14; 146 (91–292)
147.72 ± 67.64; 134 (59–313)
Female
133.43 ± 41.85; 127 (67–228)
158.75 ± 54.35; 139.5 (100–263)
133.31 ± 59.86; 131 (67–313)
Male
157.12 ± 77.71; 133.5 (80–387)
177.27 ± 66.77; 146 (91–292)
159.44 ± 73.12; 141.5 (59–300)
, (ng/dL)
105.30 ± 19.99; 99 (77–159)
111.11 ± 16.74; 110 (89–159)
106.90 ± 23.84; 99 (72–159)
Female
105.93 ± 23.42; 97 (84–159)
108.17 ± 14.76; 110.5 (89–133)
106.07 ± 31.36; 95 (72–159)
Male
104.75 ± 17.22; 99 (77–138)
113.47 ± 18.33; 110 (91–159)
107.62 ± 15.67; 99 (86–136)
T4, (mg/dL)
9.48 ± 1.65; 9.50 (6–13.1)
9.18 ± 1.49; 9.20 (5.9–12.3)
8.93 ± 1.19; 8.60 (6.5–10.9)
Female
9.52 ± 1.78; 9.50 (7.4–13.1)
9.55 ± 1.26; 9.20 (8–12.3)
8.81 ± 0.95; 8.60 (7.5–10.9)
Male
9.44 ± 1.58; 9.65 (6–12)
8.91 ± 1.62; 9.20 (5.9–11.2)
9.03 ± 1.39; 8.95 (6.5–10.7)
TSH, (mIu/L)
2.82 ± 1.96; 2.28 (0.5–8.2)
2.07 ± 1.25; 1.76 (0.9–6.6)
2.65 ± 1.63; 2.67 (0.8–6.8)
Female
2.80 ± 1.92; 2.58 (0.5–7.3)
2.23 ± 1.13; 2.02 (0.9–4.6)
2.65 ± 1.30; 2.79 (0.8–5.0)
Male
2.84 ± 2.07; 1.99 (0.9–8.2)
1.94 ± 1.36; 1.66 (1.1–6.6)
2.64 ± 1.91; 2.28 (0.8–6.8)
Data are expressed as mean ± SD; median (range). The mean PRL level was significantly higher in the pretreatment serum of the patients compared with their posttreatment levels (paired -test, ). Patients had a significant increase in their serum cortisol levels after achieving PASI 75 (Wilcoxon signed-rank test, ). A significant increase was observed in plasma T3 levels of patients after achievement of PASI 75 (Wilcoxon signed-rank test, ).
